Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease
cAMP and PKA are important signaling molecules responsible for GLP-1R-mediated effects, which have been shown in neurons and non-neuronal cells [63,64,65,66,67,68,69,70]
Ultimately, the decision to continue or discontinue GLP-1 treatment after reaching your weight loss goal should be based on a comprehensive assessment of your individual health needs, potential benefits, and any risks associated with long-term use of the medication
Resistance training three or more times per week compound movements, progressive load is the evidence-based standard for maintaining lean tissue during this period